ACI-35.030, an experimental anti-tau vaccine that AC Immune is developing for Alzheimer’s disease, was able to potently induce an immune response as intended and was generally well-tolerated, according to 10-week interim data from a Phase 1/2 clinical trial. “These latest interim results add to the robust clinical dataset supporting plans for continued late-stage development,” Andrea Pfeifer, PhD, CEO of AC Immune, said in a press release. Recommended Reading January 27, 2022 News by Yedida Y…
You must be logged in to read/download the full post.
The post Anti-pTau Vaccine Induces Intended Immune Response in Ongoing Trial appeared first on BioNewsFeeds.